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Background: Asthma has been associated with suicidal ideation (SI), though the mechanisms
remain poorly understood. Some asthma medications (e.g., theophylline and beta-2 adrenergic
agonists) have been shown to provoke feelings of anxiety, fear, and irritability, but their link to
SI among asthmatics has not been examined, which was the purpose of the present study.
Methods: 664 adult asthma outpatient (39% male, M ageZ 49  14.3) underwent a sociodemo-
graphic, psychiatric, and medical history interview. Patients reported asthma medication use,
which was verified by chart review. All patients underwent spirometry and completed ques-
tionnaires including the beck depression inventory-II (BDI-II) which includes an item that
assesses SI in the past two weeks.
Results: 11.5% of patients reported having SI in the past two weeks. After adjusting for age,
sex, smoking, asthma severity, and depressive disorders, analyses indicated that theophylline
use was associated with an increased likelihood of SI (ORZ 2.67, 95% CIZ 1.07e6.65). Sensi-
tivity analyses including asthma control levels and benzodiazepine use as additional covariates
did not alter this association (respectively: OR Z 2.54, 95% CI Z 1.04e6.37; OR Z 2.71, 95%
CI Z 1.09e6.78), though adding cohabitation rendered it no longer statistically significant
(OR Z 2.34, 95% CI Z 0.90e6.09). There were no associations between SI and LABA use.t of Psychology, University of Quebec at Montreal (UQAM), P.O. Box 8888, Succursale Center-Ville,
el.: þ1514 987 3000 3835; fax: þ1514 987 7953.
tss.qc.ca, kiml_lavoie@yahoo.ca (K.L. Lavoie).
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934 H. Favreau et al.Conclusions: Findings suggest that theophylline but not LABA use may be associated with an
increased risk of SI among adult asthmatics independent of depressive disorders, asthma
control levels, and asthma severity, but not cohabitation, suggesting that cohabitation may
be important for SI in this population. Physicians should be cautious when prescribing theoph-
ylline or similar agents to asthmatics, and ensure adequate follow-up.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Suicide is the fourth leading cause of death in Canada among
adults aged 45e54, after cancer, cardiovascular diseases, and
unintentional injuries.1 Multiple factors may explain suicidal
behavior (an inclusive term used to refer to the spectrum of
behaviors related to suicide including suicidal ideation,
attempted suicides, and completed suicides). Notably,
chronic illness has been identified as an important risk factor
for suicidal behavior.2e5 Among several chronic illnesses
(cardiovascular disease, hypertension, asthma, chronic bron-
chitis, cancer, arthritis, diabetes, gout, lupus, thyroid, liver
and renal disorder) pulmonary diseases (including asthma)
have been shown to have the strongest association with
suicidal behavior.3,6 Surprisingly, major depression, drug and/
or alcohol dependence, and sociodemographic characteristics
such as age, sex, ethnicity, income, and years of education, do
not seem to alter the association between pulmonary disease
and suicidal behavior,3,6,7 despite the fact that these variables
are generally identified as risk factors.8e13 These perplexing
results highlight the importance of understanding how
patients with asthma can manifest suicidal behavior.
Asthma is associated with sometimes unpredictable and
potentially life-threatening attacks. Financial losses may be
incurred as a result of treatment (e.g., medication expenses,
hospitalization) and/or asthma-related work absenteeism.
Aside from the impact of these psychosocial factors, other
variables may explain increased suicidal behavior among
asthmatics. Significant adverse psychological effects,
including agitation, anxiety, and depression have been shown
to be associated with sustained use of theophylline14e18 and
beta-2 adrenergic agonists,14,17,19 both of which are bron-
chodilator medications. However, the potential mechanisms
linking asthma to suicidal behavior remain poorly understood.
To our knowledge, no study has ever explored the association
between daily use of bronchodilators (i.e., theophylline and
long-acting beta-2 adrenergic agonists, LABA) and suicidal
behavior in this population.
The aim of the present study was to evaluate the risk for
suicidal ideation (SI) associated with bronchodilator medi-
cations that are prescribed on a daily basis (theophylline and
LABA’s), in a large sample of Canadian adult patients with
asthma. It was hypothesized that theophylline and LABA use
would be associated with a significantly increased risk of SI
among adult asthmatics, independent of covariates.
Method
Sample
This is a sub-analysis of a larger prospective cohort study
(PAL Study: Psychological factors in Asthma LongitudinalStudy), which was designed to assess psychological and
behavioral risk factors for asthma morbidity. For the main
study, a total of 801 consecutive adults with physician-
diagnosed asthma were recruited from the outpatient
asthma clinic of Hoˆpital du Sacre´-Coeur de Montre´al
between June 2003eJanuary 2007. Asthma was confirmed
by chart evidence of a reversibility of bronchial obstruction
(increase in FEV1 of 15% after inhaled salbutamol) or
bronchial hyperresponsiveness tomethacholine challenge.20
Patients were eligible if they were between the ages of 18
and 75 years and were French or English speaking. Patients
were excluded if they had occupational asthma, a comorbid
medical condition that significantly impacted health
outcomes (e.g., chronic obstructive pulmonary disease,
cardiovascular disease), evidence of severe psychopa-
thology (e.g., psychosis), current substance abuse, or
cognitive deficits such that they were not able to give
consent. Of 801 patients recruited, 137 patients had missing
data for both the independent and dependent variables and
were thus excluded from the analyses, leaving a final sample
of 664 patients. This project was approved by the Ethics
Committee of Hoˆpital du Sacre´-Cœur de Montre´al, and
written consent was obtained from all participants.
Procedure
A single clinical research assistant recruited patients
following their clinic visit in the outpatient asthma clinic of
Montreal’s Sacre´-Coeur Hospital. All patients underwent
a sociodemographic and medical/asthma history interview,
as well as standard pulmonary function tests (spirometry).
As part of the medical/asthma history interview, patients
self-reported medication use, which was verified by chart
review. Patients then underwent a brief structured
psychiatric interview using the Primary Care Evaluation of
Mental Disorders,24 and completed a series of self-report
questionnaires assessing psychological factors, including
depression (which included an assessment of SI) and levels
of asthma control.
Measures
Sociodemographic and medical/asthma history
At the time of recruitment, patients provided information
about their sociodemographic characteristics and their
medical and asthma history. The following information was
collected: age, sex, ethnicity, whether they were cohab-
itating (living with a partner), employment status, level of
education, smoking history, body mass index (BMI), pres-
ence of medical comorbidities, date of initial asthma
diagnosis, presence of atopy, and current asthma medica-
tion prescriptions. Asthma severity was assessed according
Suicidal ideation and asthma medications 935to GINA guidelines.21 All medical history information and
prescription data were verified by chart review in consul-
tation with the treating physician.
Primary care evaluation of mental disorders (PRIME-MD)
The PRIME-MD is a brief, structured psychiatric interview
that evaluates a range of psychiatric disorders that tend to
present in primary care settings (i.e., mood, anxiety,
somatoform, eating, and substance abuse disorders). For
the purposes of this sub-study, only the mood disorders
module,24 which was administered by a trained, clinical
research assistant and was supervised by a licensed clinical
psychologist (KL), is considered. The PRIME-MD has good
psychometric properties. It uses Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV-R)22 criteria to generate
diagnoses that have been shown to be of comparable reli-
ability (kappa Z 0.71), sensitivity (83%) and specificity
(88%) for diagnoses of mood disorders as longer structured
interviews such as the Structured Clinical Interview for DSM
(SCID).23e25
Suicidal ideation: question 9 of the Beck Depression
Inventory-II (BDI-II)
The BDI-II26,27 is a self-report questionnaire containing 21
items designed to measure the intensity of depressive
symptoms over the past two weeks. Question 9 on the BDI-II
evaluates SI. For this question, the patient chooses the
response that best describes how he or she has been feeling
during the past two weeks including the day on which the
questionnaire is completed. The response options for
question 9 include: 0Z “I don’t have any thoughts of killing
myself,” 1Z “I have thoughts of killing myself, but I would
not carry them out,” 2 Z “I would like to kill myself,”
3 Z “I would kill myself if I had the chance.” For analytic
purposes, responses 1 through 3 were considered indicative
of SI.
Asthma control questionnaire
The Asthma Control Questionnaire (ACQ; 29) is a self-report
questionnaire designed to evaluate a patient’s level of
control of their asthma according to specific international
(GINA) criteria.21 The ACQ measures asthma symptoms
(shortness of breath, wheezing, daytime and nighttime
dyspnea), activity limitations, and bronchodilator use in
the past week. An additional question concerning spirom-
etry results (% of predicted FEV1) is completed by the
research assistant following the patients pulmonary func-
tion testing. The ACQ comprises 7 items on a 7-point scale
(0 Z good control, 6 Z poor control). The ACQ has
demonstrated strong measurement properties, with intra-
group correlation coefficients of 0.90e0.95, good
construct validity and good cross-sectional and longitudinal
validity.28e30
Pulmonary function testing
According to standard procedure, spirometry has been used
to assess pulmonary function as part of the patients asthma
clinic visit. At least 4 h before all tests, rescue medication
was withheld, and predicted values of FEV1 and FVC were
calculated from reference values for patients less than31
and greater32 than 70 years respectively, yielding % pre-
dicted FEV1 and % predicted FEV1/FVC.Statistical analyses
Imputation of missing data
Multiple imputation is the method of choice for studies with
missing values that affect less than 60% of the sample.33 The
imputationmethod used assumed that the data weremissing
at random, and included all covariates that were included in
the final logistic analyses. Using PROC MI in SAS v9.1 (SAS
Institute, Cary, NC, USA), we produced five independent
replicated datasets. Each imputed dataset comprised 664
patients, which was the final sample size used for analyses in
this study. For the main analyses, estimation for model
coefficients was produced using PROC MINIANALYZE, which
averages all estimates and adjusts standard errors according
to Rubin’s rule.34 Details of the amount of missing data per
variable are presented in Table 1.
Baseline analyses
Group differences in sociodemographic, medical/asthma
history, and medication use between patients with and
without SI were examined using General Linear Models
(GLM’s). For these analyses, the original non-imputed
dataset was used.
Main analyses
Two logistic regression model analyses were carried out to
examine the specific effects of each type of medication:
theophylline and LABA use, on SI. Both models adjusted for
age, sex, years of education, mood disorders (including
major/minor depression and/or dysthymia), smoking
status, and asthma severity, determined a priori based on
previously documented impacts on suicidal behavior.3,6e13
Results
Sociodemographic and asthma characteristics
Thirty nine percent of participants were male (n Z 259)
and the mean age  SD of the sample Z 49  14 years. A
total of 76 patients (11.5%) reported having SI according to
responses on the BDI-II.
Sociodemographic characteristics presented as a func-
tion of SI (yes, no) are presented in Table 1. Patients
reporting SI were significantly more likely to live alone than
patients not reporting SI. There were no other significant
group differences in sociodemographic characteristics.
Asthma characteristics presented as a function of SI are
also presented in Table 1. Patients reporting SI were
significantly more likely to have higher scores on the ACQ
(indicating worse asthma control) but had better pulmonary
function (higher FEV1 % predicted). This discrepancy may
be explained by the fact that disease control is better
measured by assessing bronchodilator reversibility of FEV1
rather than baseline (resting) levels of FEV1, the former of
which was not assessed in the present study. Also, they
were significantly more likely to be current smokers and
have a heavier smoking history (greater number of pack-
Table 1 Sociodemographic, clinical, asthma and asthma medications characteristics as a function of suicidal ideation.
Suicidal ideation
n (%) or M  SD Yes 76
(11.5)
No 588
(88.5)
F p Missing
data% (n)
Sociodemographics
Age (yr) 48  13.5 50  14.3 0.83 0.362 _
Sex (male) 25 (33) 235 (40) 1.41 0.235 _
Ethnicity (Caucasian) 71 (93) 547 (93) 0.01 0.939 _
Lives alone 46 (60) 176 (30) 28.19 <0.0001 2 (10)
Years of education 12.9  4.45 13.1  3.47 0.26 0.610 2 (11)
Employed 39 (51) 365 (62) 3.70 0.055 2 (10)
Clinical and asthma characteristics
Asthma Control Questionnaire (ACQ)a 1.8  1.0 1.4  1.0 8.91 0.003 _
Duration of asthma (years) 18.7  17.8 19.4  15.4 0.13 0.718 2 (13)
FEV1, % predicted
b 85  20 79  23 4.50 0.034 8 (53)
FEV1/FVC, % predicted
b 74  10 72  13 1.51 0.220 12 (56)
Atopy 54 (71) 417 (71) 0.00 0.952 1 (7)
Pack-yearsc 12.9  19.4 8.3  14.7 5.66 0.018 15 (97)
Current smoker 12 (16) 41 (07) 6.78 0.009 _
Mood disorders 37 (49) 76 (13) 65.03 <0.0001 e
Benzodiazepines use 16 (21) 65 (11) 6.28e 0.012 _
Asthma medications
Use of short-acting bronchodilatator
(# puffs/week)d
10  20.9 8.0  14.1 1.92 0.166 1 (7)
Short-acting b2 adrenergic, anticholinergic 75 (99) 570 (97) 0.42 0.516 1 (3)
Long-acting bronchodilators (LABA’s)
(alone or combined)
49 (64) 388 (66) 0.17 0.682 1 (3)
Inhaled corticosteroids (ICS)
(alone or combined)
70 (92) 553 (94) 0.31 0.578 1 (3)
Oral corticosteroids 9 (12) 47 (8) 1.44 0.2305 1 (4)
Anti-leukotrienes 11 (8) 12 (71) 0.08 0.779 1 (3)
Theophylline 11 (8) 5 (29) 3.18 0.075 1 (3)
Anti-rhinitics 19 (14) 17 (100) 0.12 0.730 1 (3)
a Higher score Z worse control.
b FEV1 Z Forced expiratory volume in 1 s; FVC Z Forced vital capacity.
c Pack-years Z average number of packs (20 cigarettes) smoked per day multiplied by the number of years smoked.
d Value is M  SD.
e Chi-square value.
936 H. Favreau et al.years) than patients not reporting SI. Finally, patients
reporting having SI were significantly more likely to have
mood disorders (including major/minor depression and/or
dysthymia) than patients not reporting having SI. There
were no other significant group differences in asthma
characteristics.
Asthma medications presented as a function of SI are
presented in Table 1. There were no significant differences
in rates of medication use among patients with versus
without SI.
Multivariate association between asthma
medications and suicidal ideation
Results of multivariate logistic regression model analyses
examining the association between asthma medication use
(theophylline, LABA) and SI are presented in Tables 2 and 3.
Though no significant association between LABA use and SI
was found (OR Z 1.02, 95% CI Z 0.56e1.84), theophylline
use was found to be significantly associated with anincreased risk of SI (OR Z 2.67, 95% CI Z 1.07e6.65) after
covariate adjustment.Sensitivity analysis: assessing the impact of
cohabitation, asthma control, and benzodiazepine
use
Though cohabitation status (i.e., living alone) has been
linked to SI in previous studies, this link has been incon-
sistent6,13,35 which is why it was not included as a covariate
a priori. However, the exceptionally high rate of living
alone (60%) in the SI group relative to the no-SI group (30%)
was unexpected, so we ran an extra set of analyses
including cohabitation as an additional covariate. Although
the risk of SI was still more than two-fold greater among
patients taking theophylline, adjustment for cohabitation
rendered the association between theophylline use and SI
no longer statistically significant (see Table 2). In addition,
both asthma control levels and benzodiazepine use were
Table 2 Multivariate logistic regression analysis examining the effects of theophylline on suicidal ideation.
Sensitivity analysis
Model with
cohabitation
Model with
asthma control
Model with
benzodiazepines use
Variable ORa 95% CI ORa 95% CI ORa 95% CI ORa 95% CI
Theophylline 2.67 1.07 6.65 2.34 0.90 6.09 2.54 1.04 6.37 2.71 1.09 6.78
Mood disorder 6.21 3.66 10.54 5.86 3.40 10.08 5.48 3.18 9.45 5.89 3.44 10.10
Asthma severity
(GINA category)
0.77 0.47 1.28 0.78 0.47 1.30 0.63 0.34 1.19 0.77 0.47 1.28
Current smoking 1.73 0.79 3.79 1.64 0.73 3.72 1.57 0.71 3.49 1.66 0.75 3.67
Age 1.00 0.98 1.02 1.01 0.99 1.03 1.00 0.98 1.02 1.00 0.98 1.02
Sex (male) 0.84 0.49 1.43 0.94 0.54 1.64 0.82 0.48 1.41 0.86 0.50 1.47
Years of education 0.99 0.92 1.06 0.99 0.92 1.07 0.99 0.92 1.07 0.99 0.92 1.07
Cohabitation 0.33 0.19 0.56
Asthma control
(ACQ scores)
1.32 0.95 1.83
Benzodiazepines use 1.43 0.45 2.87
a Covariate adjusted.
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ACQ Z 1.8, 21% taking benzodiazepine) versus without
(score on ACQ Z 1.4, 11% taking benzodiazepine) SI. Extra
analyses including asthma control or benzodiazepine as an
additional covariate, showed no effect on the association
between theophylline use and SI (see Table 2).Discussion
The present study assessed the prevalence of suicidal
ideation (SI) among adult, tertiary care patients with
asthma, and the association between certain asthma
medications (i.e., daily use bronchodilators: theophylline
and LABA) and SI. Results revealed that 11.5% of adult
asthmatics reported having SI in the last two weeks,
which is nearly four times greater than the 12-monthTable 3 Multivariate logistic regression analysis examining the
Sensitivity an
Model with
cohabitation
Variable ORa 95% CI ORa 95%
LABA’s 1.02 0.56 1.84 1.02 0.55
Mood disorder 6.02 3.57 10.16 5.73 3.35
Asthma severity
(GINA category)
0.83 0.49 1.40 0.83 0.48
Current smoking 1.85 0.85 4.02 1.73 0.77
Age 1.00 0.98 1.02 1.00 0.99
Sex (male) 0.85 0.50 1.46 0.97 0.56
Years of education 0.98 0.91 1.06 0.99 0.92
Cohabitation 0.31 0.18
Asthma control
(ACQ scores)
Benzodiazepines use
a Covariate adjusted.prevalence (2.9%) found in a comparable age group
(45e64 years) of the general Quebec population.36 It is
therefore possible that the observed prevalence of 11.5%
would have been even greater if, as in the general Quebec
population, it had been measured over a period of 12
months. This finding is consistent with earlier studies
demonstrating a high prevalence of suicidal behaviors
among asthmatic adults.3,6,7,37,38
We expected both theophylline and LABA use to be
associated with a significantly increased risk of SI among
adult asthmatics, independent of covariates. Our hypoth-
eses were partially confirmed: although there was no
increased risk of SI associated with LABA’s, theophylline use
increased the likelihood of SI in adult asthmatics nearly
three-fold. This was found to be independent of several
important covariates including having a comorbid mood
disorder, asthma severity, levels of asthma control, age,effects of LABA’s on suicidal ideation.
alysis
Model with asthma
control
Model with
benzodiazepines use
CI ORa 95% CI ORa 95% CI
1.86 1.09 0.59 2.02 1.02 0.56 1.85
9.83 5.29 3.08 9.08 5.73 3.36 9.77
2.21 0.66 0.33 1.29 0.83 0.49 1.40
3.87 1.65 0.75 3.65 1.80 0.83 3.92
1.03 1.00 0.98 1.02 1.00 0.98 1.02
1.68 1.20 0.49 1.43 0.88 0.51 1.50
1.06 0.99 0.92 1.07 0.99 0.92 1.06
0.54
1.34 0.96 1.87
1.39 0.70 2.79
938 H. Favreau et al.sex, years of education, smoking status, and benzodiaze-
pine use. To our knowledge, no prior studies have identified
an increased risk of SI associated with theophylline use in
adult asthmatics. However, our results are consistent with
two previously reported case studies: one reporting an
association between SI and theophylline use in an adult
with COPD,39 and one reporting an association between
theophylline use and depression in a patient with asthma.16
Also consistent with our results, symptoms of agitation,
irritability, anxiety, and psychosis have been reported in
case studies of adult asthmatics taking theophylline at
therapeutic doses.18,40e45
The fact that the risk of SI associated with theophylline
use became non-significant after further adjustment for
cohabitation suggests that cohabitation may be important
to SI in this population. The impact of cohabitation was
examined separately due to the fact that all covariates
were chosen a priori based on well established associations
with the independent or dependent variables. However,
previous studies demonstrating a link between cohabitation
have been inconsistent, with some showing significant
associations between being single or living alone and an
increased risk of SI,6,13,35 and others not,8,10 which made it
difficult to assess the pertinence of this variable. Moreover,
with the exception of one study,6 previous studies were not
conducted among patients with asthma or other chronic
diseases, which also suggested that cohabitation may not
be relevant to an asthma population. Nonetheless, our
findings indicate that the majority (60%) of patients with SI
lived alone, and suggests that cohabitation may in part
mediate the association of SI and theophylline use. Poten-
tial mechanisms of this effect are detailed below.
Aside from theophylline and cohabitation, only one
other variable was independently associated with SI in this
study: mood disorders. The association between mood
disorders and SI is not surprising, given that SI is included
among the diagnostic criteria for mood disorders46 and is
highly comorbid with depression.6,47 However, it is note-
worthy that mood disorders were unable to account for the
association between theophylline and SI in this population,
suggesting that the results are not simply the result of
comorbid depression.Potential mechanisms: theophylline
Although the present study was not designed to examine the
mechanisms potentially linking theophylline use to
increased SI, we could speculate on some of the potential
pathways. First, theophylline may be related to SI in asth-
matics via psychophysiological mechanisms involving the
central nervous system (CNS). Theophylline stimulates
the CNS, acts as a bronchial smooth muscle relaxant,
and increases cerebral blood resistance (whichmay diminish
cerebral blood flow and cerebral oxygen), which may
provoke intense feelings of agitation, dyspnea, hyperventi-
lation, and dizziness.14,46 In addition, when theophylline is
administered at higher doses (>18 mg/L), it can also induce
other symptoms including nausea, tachycardia, agitation,
trembling, hallucinations, and irritability.14,48 Theophylline
increases blood levels of catecholamines14,49 in a patho-
physiological manner similar to panic disorder,50,51 whichhas been shown to be significantly associated with the
presence of SI in patients with asthma.52
Other mechanisms potentially linking theophylline to
increased SI include pharmacokinetics (absorption, distri-
bution, metabolism, and elimination of theophylline) and
pharmacodynamics (interactions between theophylline and
other medications). For theophylline to be effective and to
avoid toxic reactions, the recommended plasma concen-
trations fall within the narrow range of 8e18 mg/L48 or
50e100 mmol/L.49 However, elevated plasma levels of
theophylline (>18 mg/L) may be common, especially within
a tertiary care population, despite being prescribed at
therapeutic doses.53 Although we did not collect data on
the circulating levels of theophylline in the patients, it is
possible that those with SI might have higher concentra-
tions due to disrupted pharmacokinetics. If this is the case
in the current study, due to the design, we would not be
able to disentangle the causal direction of this relationship.
For pharmacodynamics, interactions with certain antibi-
otics (e.g., erythromycine, clarithromycine, ciprofloxacin)
that are often prescribed to asthmatics,54,55 may signifi-
cantly increase plasma levels of theophylline through
competitive inhibition.55 Thus, it is possible that combining
theophylline with certain antibiotics may give rise to
adverse psychological effects such as anxiety or irritability.
Unfortunately, we did not collect data on recent antibiotic
use in this sample, so we cannot confirm this hypothesis.
However, the present study included stable outpatients
with no recent (i.e., last 4 weeks) emergency care visits for
exacerbations, which reduces the likelihood that patients
were taking concomitant antibiotics at the time of their
recruitment.
Another interaction effect could be with certain
benzodiazepines (diazepam and alprazolam) for which
theophylline may have an antagonistic effect.56,57 At
a cellular level, theophylline inhibits benzodiazepines57,58
by binding to the same receptors (blocking adenosine
receptors possibly related to GABA-benzodiazepines). In
the current study, 21% of patients with SI reported taking
benzodiazepines at least occasionally, which is nearly two
times greater than those without SI (11%) (see Table 1).
However, taking benzodiazepines had no effect on the
significant association between theophylline use and SI (see
Table 2), which suggests that higher benzodiazepine use is
unlikely to account for our findings.
Potential mechanisms: cohabitation
The significant association between theophylline and SI was
rendered non-significant after additional adjustment for
cohabitation, suggesting that cohabitation status may be
important to SI among asthmatics. Though we did not assess
this directly, there are several possible explanations for this
finding. Living alone or being unmarried has been shown to
increase depression,59 alcohol and substance abuse,60
anxiety and hopelessness,61 and suicidal behaviors (SI and
actual suicide) among primary care patients and those with
completed suicides (the latter determined following
autopsy).6,13 Moreover, living alone increases the risk of
being less compliant to treatment in patients with a chronic
disease.62 Therefore, living with someone may be
a protective factor against SI by having increased access to
psychological or social support, by ensuring better
Suicidal ideation and asthma medications 939compliance to treatment, and by having help to engage in
self-management behavior.63e65 Clinically, our findings
suggest the importance of providing support for asthma
patients who live alone, though this needs to be fully
explored in future research.
Study limitations and strengths
The present study has certain limitations that need to be
taken into account. Firstly, asking patients to self-report
whether they are experiencing any suicidal thoughts is the
most direct method of assessing SI. However, patients may
choose not to disclose suicidal thoughts. Thus, the preva-
lence of SI may have been underestimated in the present
study. Current medication use was also self-reported in the
present study, though this data was systematically verified
via chart review. It was also not possible to verify medi-
cation adherence in the present study. As such, we cannot
verify the extent to which patients prescribed theophylline
actually took it, or for how long, or at what doses. Our
measure of cohabitation was limited to the number and
type of persons the patient lived with, so we cannot
comment on the quality of relationships or degree of social
support actually received by patients. The cross-sectional
nature of the present study also limits the conclusions that
may be drawn, so no causal inferences can be drawn.
Longitudinal studies are needed to elucidate the temporal
relationship between asthma, theophylline use, cohabita-
tion, and SI. Finally, the present study included patients
presenting to a tertiary care clinic, and so the results may
not be generalizable to asthma patients treated in primary
care or in community settings.
Despite these limitations, the present study also has
a number of important strengths. First, SI was assessed
using a question from a well-validated questionnaire (BDI-
II). Second, all self-reported medication use was system-
atically verified by chart review. Third, this study makes
a novel contribution to the existing literature by being the
first, to out knowledge, to examine the association
between chronic bronchodilator use and SI in a large
(n Z 664) sample of patients with objectively documented
physician-diagnosed asthma. Finally, we demonstrated
links between theophylline use and SI after examining the
effect of multiple risk factors for suicidal behavior
including mood disorders (depression), disease severity,
asthma control, benzodiazepines use, smoking, age, sex,
and level of education. However, the addition of cohabi-
tation status to the model rendered the theophylline-SI link
non-significant, suggesting that asthmatics who live alone
may be particularly susceptible to SI.Conclusion
In conclusion, the present study found significant associa-
tions between theophylline use and SI in a sample of adult,
tertiary-care asthmatics, independent of several covariates
including mood disorders, asthma severity and asthma
control. However, after further adjustment for cohabita-
tion, this association was no longer statistically significant,
suggesting that cohabitation (i.e., living alone) may be
a risk factor for SI in asthmatics (or conversely, that living
with someone may be protective against SI). These findingsindicate that physicians should be vigilant for patients who
may be at increased risk of SI (i.e., those with a suspected
or confirmed mood disorder, those requiring potent bron-
chodilators such as theophylline), particularly in patients
who live alone or who are anxious. Also, given the identi-
fication of multiple factors potentially influencing the
pharmacodynamic and pharmacokinetic properties of
theophylline, it may also be necessary to provide close
monitoring of plasma concentrations of theophylline in
order to evaluate the therapeutic benefits versus potential
side effects. Clinically, it may be important for clinicians to
provide additional support for patients who live alone and
receive only limited support, to screen for SI and anxiety
disorder, revise prescriptions, and refer patients for
appropriate pharmacotherapy or psychotherapeutic treat-
ment if needed.Conflict of interest statement
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